Clinicopathological Profile and Treatment Stratification in Urinary Bladder Cancer
A Retrospective Study
DOI:
https://doi.org/10.37376/benunivmedj.v3i1.7888Keywords:
Urinary bladder cancer (UBC), clinicopathological characteristics, tumor staging, treatment strategies, clinical decision-makingAbstract
Background: Urinary bladder cancer (UBC) exhibits marked heterogeneity in its clinicopathological characteristics, which directly influence treatment strategies and disease behavior. Understanding the correlation between pathological features and therapeutic approaches is crucial for optimizing patient management. Aim: To evaluate the interplay between clinicopathological characteristics and treatment modalities in urinary bladder cancer and their implications for tumor behavior and clinical decision-making. Materials and Methods: This retrospective cohort study was conducted at the Department of Urology, Faculty of Medicine, Benghazi, in collaboration with the National Cancer Center, from January 2022 to December 2025. A total of 100 cases diagnosed via transurethral resection of bladder tumor (TURBT) and radical cystectomy were included. Non-neoplastic lesions were excluded. Data on demographics, clinical presentation, histopathology, tumor stage, grade, invasion status, and treatment were analyzed. Chi-square tests were used for associations, with p < 0.05 considered significant, with the calculation of odds ratios (OR) and 95% confidence intervals (CI). Results: The data showed marked male predominance (91%; ratio 10.1:1) with a mean age of 60.2 ± 4.4 years. Most patients (90%) were aged 40–80 years. Painless hematuria (58%) and smoking (87%) were predominant. Urothelial carcinoma accounted for 92% of cases. Muscle-invasive disease was present in 62%, and 66% had high-grade tumors. A significant association was observed between tumor grade and muscle invasion (χ² = 15.60, p < 0.001), with high-grade tumors being significantly more likely to present with invasive disease (OR = 5.73; 95% CI: 2.33–14.10).Treatment showed a significant association with disease category (χ² = 95.05, p < 0.001). Conclusion: UBC in this region is characterized by advanced presentation and aggressive biological behavior. The strong correlation between high grade and invasion emphasizes the urgent need for earlier detection strategies and tobacco cessation programs.
References
Compérat E, Varinot J, Moroch J, Eymerit-Morin C, Brimo F. A practical guide to bladder cancer pathology. Nat Rev Urol. 2018;15(3):143-54.
Jackson CL. Prognostic Features of Non-Muscle-Invasive Bladder Cancer: Grade, Molecular Subtype, and Tumor Immune Microenvironment [dissertation]. Kingston: Queen's University (Canada); 2021.
Moschini M, D'andrea D, Korn S, Irmak Y, Soria F, Compérat E, et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol. 2017;14(11):651-68.
Goonewardene SS, Ventii K, Bahl A, Persad R, Motiwala H, Albala D. Management of muscle-invasive bladder cancer. Cham: Springer International Publishing; 2021.
Tang L, Xu H, Wu T, Wu W, Lu Y, Gu J, et al. Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review. Discov Oncol. 2024;15(1):111.
Al-Sattar H, Ding H, Okoli O, Okoli S, Ghose A, Banna GL, et al. A multi-modal approach for decision making in bladder cancer. Nat Rev Urol. 2026:1-24.
Paner GP, Montironi R, Amin MB. Challenges in pathologic staging of bladder cancer: proposals for fresh approaches to assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances. Adv Anat Pathol. 2017;24(3):113-27.
Chourasiya Y, Bisht R, Swarn S, Gandhi SM, Kapoor DU. Surgical interventions for bladder cancer management. In: Bladder Cancer Breakthroughs. San Diego: Academic Press; 2026. p. 277-299.
Black AJ, Black PC. Variant histology in bladder cancer: diagnostic and clinical implications. Transl Cancer Res. 2020;9(10):6565.
Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384:e076723. (Note: BMJ articles typically require the elocator code instead of an open period).
Safiri S, Kolahi AA, Naghavi M, Global Burden of Disease Bladder Cancer Collaborators. Global, regional, and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease study 2019. BMJ Glob Health. 2021;6(11):e004128.
Helstrom E, Lakshmanan A, Fulmes A, Sindhani M, Isali I, Barata P, et al. Examining the concordance of patient age distribution between genitourinary (GU) clinical trials and real-world disease populations: kidney, prostate, and bladder cancer analysis. Ann Surg Oncol. 2024;31(9):5504-6.
Jakus D, Šolić I, Jurić I, Borovac JA, Šitum M. The impact of the initial clinical presentation of bladder cancer on histopathological and morphological tumor characteristics. J Clin Med. 2023;12(13):4259.
Kiebach J, Beeren I, Aben KK, Witjes JA, van der Heijden AG, Kiemeney LA, et al. Smoking behavior and the risks of tumor recurrence and progression in patients with non‐muscle‐invasive bladder cancer. Int J Cancer. 2025;156(8):1529-40.
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Escrig JL, et al. European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75-94.
Haas M, Engelmann SU, Mayr R, Gossler C, Pickl C, Kälble S, et al. A novel grading approach predicts worse outcomes in stage pT1 non‐muscle‐invasive bladder cancer. BJU Int. 2024;134(2):249-57.
Eckstein M, Matek C, Wagner P, Erber R, Büttner-Herold M, Wild PJ, et al. Proposal for a novel histological scoring system as a potential grading approach for muscle-invasive urothelial bladder cancer correlating with disease aggressiveness and patient outcomes. Eur Urol Oncol. 2024;7(1):128-38.
Matulewicz RS, Steinberg GD. Non—muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol. 2020;22(2):43-51.
Contieri R, Soloway MS, Gontero P, Herr H, Kassouf W, Mertens LS, et al. Deintensification of treatment for low-grade bladder tumors: a collaborative review by the International Bladder Cancer Group (IBCG). Eur Urol Oncol. 2025;8(1):179-89.
Naselli A, Pirola GM, Castellani D. Bacillus calmette-guérin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC): current guidance and experience from clinical practice. Res Rep Urol. 2024;16:299-305.
Li Z, Wang Z, Liu Y, Yang L, Gu L, Li H, et al. IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment. Sci Rep. 2025;15(1):4874.
Szabados BE, Guerrero-Ramos F, Grande E, Grivas P, Grünwald V, Miguel MC, et al. On the horizon: a global multidisciplinary perspective on delivering emerging therapies for patients with BCG-naive high-risk NMIBC. Oncol Ther. 2025;13(2):275-91.
Scilipoti P, Longoni M, De Angelis M, Zaurito P, Ślusarczyk A, Soria F, et al. Outcomes of BCG vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancer. BJU Int. 2025;136(1):47-54.
Keane KG, Redfern A, Lim J, Hayne D. The role of gemcitabine–docetaxel in the management of NMIBC: a scoping review of current status and future directions. Expert Rev Anticancer Ther. 2026;26(3):333-44.
Lee T, MacDonald L, Lawen T, Kamat AM. Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what’s new in 2025? Expert Rev Anticancer Ther. 2025;25(10):1181-93.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Benghazi University Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright©2024University of Benghazi.
This open Access article is Distributed under a CC BY-NC-ND 4.0 license
Copyright
